NPPA and cardiac hypertrophy: MG53 recently exhibited an anti-inflammatory function in cardiac hypertrophy by inhibiting the nuclear transfer of p65 and β-catenin, thereby downregulating their downstream target genes, including ANP, BNP, and β-MHC [22, 35].